Evidence map›Paper›PMID 34107254›Full record

ArticleCell reports2021

Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathology.

Yanling Hu, Gemma L Fryatt, Mohammadmersad Ghorbani, Juliane Obst, David A Menassa, Maria Martin-Estebane, Tim A O Muntslag, Adrian Olmos-Alonso, Monica Guerrero-Carrasco, Daniel Thomas and 2 more

Abstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yanling HuSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Gemma L FryattSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Mohammadmersad GhorbaniAntibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Juliane ObstSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
David A MenassaSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Maria Martin-EstebaneSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Tim A O MuntslagSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Adrian Olmos-AlonsoSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Monica Guerrero-CarrascoSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Daniel ThomasSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.
Mark S CraggAntibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Diego Gomez-NicolaSchool of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK. Electronic address: d.gomez-nicola@soton.ac.uk.

Funding

Cancer Research UK 24721Medical Research Council MR/P024572/1
6 · The paper itself

Abstract

The sustained proliferation of microglia is a key hallmark of Alzheimer's disease (AD), accelerating its progression. Here, we aim to understand the long-term impact of the early and prolonged microglial proliferation observed in AD, hypothesizing that extensive and repeated cycling would engender a distinct transcriptional and phenotypic trajectory. We show that the early and sustained microglial proliferation seen in an AD-like model promotes replicative senescence, characterized by increased βgal activity, a senescence-associated transcriptional signature, and telomere shortening, correlating with the appearance of disease-associated microglia (DAM) and senescent microglial profiles in human post-mortem AD cases. The prevention of early microglial proliferation hinders the development of senescence and DAM, impairing the accumulation of Aβ, as well as associated neuritic and synaptic damage. Overall, our results indicate that excessive microglial proliferation leads to the generation of senescent DAM, which contributes to early Aβ pathology in AD.

Indexed as

Amyloid beta-PeptidesAnimalsCellular SenescenceDisease Models, AnimalHumansMiceMice, TransgenicMicrogliaAmyloid beta-PeptidesAlzheimer's diseaseAPP/PS1CSF1Rdisease-associated microglia (DAM)

Identifiers

PMID34107254
PMCPMC8206957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.